Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 213

1.

A comparison of the neuronal dysfunction caused by Drosophila tau and human tau in a Drosophila model of tauopathies.

Ubhi KK, Shaibah H, Newman TA, Shepherd D, Mudher A.

Invert Neurosci. 2007 Sep;7(3):165-71. Epub 2007 Jul 18.

PMID:
17636367
2.

Drosophila models of human tauopathies indicate that Tau protein toxicity in vivo is mediated by soluble cytosolic phosphorylated forms of the protein.

Feuillette S, Miguel L, Frébourg T, Campion D, Lecourtois M.

J Neurochem. 2010 May;113(4):895-903. doi: 10.1111/j.1471-4159.2010.06663.x. Epub 2010 Feb 27.

3.

Disruption of neuronal function by soluble hyperphosphorylated tau in a Drosophila model of tauopathy.

Cowan CM, Chee F, Shepherd D, Mudher A.

Biochem Soc Trans. 2010 Apr;38(2):564-70. doi: 10.1042/BST0380564. Review.

PMID:
20298222
4.

Important neuronal toxicity of microtubule-bound Tau in vivo in Drosophila.

Talmat-Amar Y, Arribat Y, Redt-Clouet C, Feuillette S, Bougé AL, Lecourtois M, Parmentier ML.

Hum Mol Genet. 2011 Oct 1;20(19):3738-45. doi: 10.1093/hmg/ddr290. Epub 2011 Jun 24.

PMID:
21705366
5.

Over-expression of tau results in defective synaptic transmission in Drosophila neuromuscular junctions.

Chee FC, Mudher A, Cuttle MF, Newman TA, MacKay D, Lovestone S, Shepherd D.

Neurobiol Dis. 2005 Dec;20(3):918-28. Epub 2005 Jul 14.

PMID:
16023860
6.

Study of tauopathies by comparing Drosophila and human tau in Drosophila.

Chen X, Li Y, Huang J, Cao D, Yang G, Liu W, Lu H, Guo A.

Cell Tissue Res. 2007 Jul;329(1):169-78. Epub 2007 Apr 4.

PMID:
17406902
7.

Transgenic zebrafish as a novel animal model to study tauopathies and other neurodegenerative disorders in vivo.

Paquet D, Schmid B, Haass C.

Neurodegener Dis. 2010;7(1-3):99-102. doi: 10.1159/000285515. Epub 2010 Feb 18.

PMID:
20173336
8.

Overexpression of tau results in defective synaptic transmission in Drosophila neuromuscular junctions.

Chee F, Mudher A, Newman TA, Cuttle M, Lovestone S, Shepherd D.

Biochem Soc Trans. 2006 Feb;34(Pt 1):88-90.

PMID:
16417489
9.

Misfolded tau protein and disease modifying pathways in transgenic rodent models of human tauopathies.

Zilka N, Korenova M, Novak M.

Acta Neuropathol. 2009 Jul;118(1):71-86. doi: 10.1007/s00401-009-0499-y. Epub 2009 Feb 24. Review.

PMID:
19238406
10.

Neuron-selective toxicity of tau peptide in a cell culture model of neurodegenerative tauopathy: essential role for aggregation in neurotoxicity.

Zhao K, Ippolito G, Wang L, Price V, Kim MH, Cornwell G, Fulenchek S, Breen GA, Goux WJ, D'Mello SR.

J Neurosci Res. 2010 Nov 15;88(15):3399-413. doi: 10.1002/jnr.22485.

PMID:
20882568
11.

Truncated tau expression levels determine life span of a rat model of tauopathy without causing neuronal loss or correlating with terminal neurofibrillary tangle load.

Koson P, Zilka N, Kovac A, Kovacech B, Korenova M, Filipcik P, Novak M.

Eur J Neurosci. 2008 Jul;28(2):239-46. doi: 10.1111/j.1460-9568.2008.06329.x.

PMID:
18702695
12.

Identification and characterization of the Drosophila tau homolog.

Heidary G, Fortini ME.

Mech Dev. 2001 Oct;108(1-2):171-8.

13.

Cytoskeleton proteins are modulators of mutant tau-induced neurodegeneration in Drosophila.

Blard O, Feuillette S, Bou J, Chaumette B, Frébourg T, Campion D, Lecourtois M.

Hum Mol Genet. 2007 Mar 1;16(5):555-66. Epub 2007 Feb 19.

PMID:
17309878
14.

Targeted Downregulation of dMyc Suppresses Pathogenesis of Human Neuronal Tauopathies in Drosophila by Limiting Heterochromatin Relaxation and Tau Hyperphosphorylation.

Chanu SI, Sarkar S.

Mol Neurobiol. 2017 May;54(4):2706-2719. doi: 10.1007/s12035-016-9858-6. Epub 2016 Mar 21.

PMID:
27000837
15.

Modulation of tau pathology in tau transgenic models.

Brion JP, Ando K, Heraud C, Leroy K.

Biochem Soc Trans. 2010 Aug;38(4):996-1000. doi: 10.1042/BST0380996. Review.

PMID:
20658992
16.

Tauopathies.

Hernández F, Avila J.

Cell Mol Life Sci. 2007 Sep;64(17):2219-33. Review.

PMID:
17604998
17.

Posttranslational modifications of tau--role in human tauopathies and modeling in transgenic animals.

Chen F, David D, Ferrari A, Götz J.

Curr Drug Targets. 2004 Aug;5(6):503-15. Review.

PMID:
15270197
18.

GSK-3beta inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila.

Mudher A, Shepherd D, Newman TA, Mildren P, Jukes JP, Squire A, Mears A, Drummond JA, Berg S, MacKay D, Asuni AA, Bhat R, Lovestone S.

Mol Psychiatry. 2004 May;9(5):522-30. Erratum in: Mol Psychiatry. 2004 Aug;9(8):812.

PMID:
14993907
19.

Abeta exacerbates the neuronal dysfunction caused by human tau expression in a Drosophila model of Alzheimer's disease.

Folwell J, Cowan CM, Ubhi KK, Shiabh H, Newman TA, Shepherd D, Mudher A.

Exp Neurol. 2010 Jun;223(2):401-9. doi: 10.1016/j.expneurol.2009.09.014. Epub 2009 Sep 24.

PMID:
19782075
20.

Abnormal bundling and accumulation of F-actin mediates tau-induced neuronal degeneration in vivo.

Fulga TA, Elson-Schwab I, Khurana V, Steinhilb ML, Spires TL, Hyman BT, Feany MB.

Nat Cell Biol. 2007 Feb;9(2):139-48. Epub 2006 Dec 24.

PMID:
17187063

Supplemental Content

Support Center